CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 134 enrolled
Drug / intervention
Radiesse injectable implant (dermal filler) +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04647721
NCT04647721N/ACompleted
CompareCT.gov

Evaluation of the Effectiveness and Safety of Radiesse for the Correction of Moderate to Severe Nasolabial Folds

Merz North America, Inc.·interventional·Posted Dec 1, 2020·Updated Jan 23, 2023

In Brief

A clinical study evaluating Radiesse injectable implant (dermal filler) and Restylane injectable implant (dermal filler) for Correction of Moderate to Severe Nasolabial Folds (NLFs). Completed, enrolled 134 participants across 7 sites.

Detailed Summary

Effectiveness: The purpose of this study is to demonstrate the non-inferiority of Radiesse (CaHA) to Restylane (HA) following subdermal implantation for the correction of moderate to severe facial wrinkles and folds, such as NLFs. Safety: To evaluate the incidence and type of adverse events and serious adverse events.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCorrection of Moderate to Severe Nasolabial Folds (NLFs)
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedDec 1, 2020
Enrollment StartJan 13, 2021
Primary CompletionNov 8, 2021
Study CompletionApr 27, 2022
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 5.6 years ago

Interventions

Radiesse injectable implant (dermal filler)device

Subdermal injection.

Restylane injectable implant (dermal filler)device

Subdermal injection.